Lion's Mane

What is Lion’s Mane?

Lion’s mane is a medicinal wood-rotting fungus with a characteristic growth pattern that resembles the shaggy mane of a lion. It prefers temperate forests in North America, Europe, and Asia, where it thrives on living oak, beech, or conifer trees.

The medicinal benefits of lion’s mane primarily involve the nervous system, and modern applications use the mushroom for general cognitive health and as a natural nootropic. It is also eaten as a delicacy — with a flavour similar to lobster when cooked with butter. In recent years it has caught the eye of the nootropic community for its ability to up-regulate nerve growth factor.

How Is Lion’s Mane Used?

Lion’s mane is mainly used for neurodegenerative disorders like dementia and multiple sclerosis, and is popular as a nootropic for supporting optimal cognitive function long term. Most people take it as a powdered capsule or tincture on a daily basis. As with most medicinal mushrooms, the biggest benefit comes from regular use over long periods rather than short bursts.

Traditional Use

Lion’s mane has a long history of use in Eastern Asia — including China, Korea, and Japan — for treating neurological disorders such as neurasthenia and age-related cognitive decline, as well as for general health.

Mycological Information

The Hericiaceae family of fungi are saprophytic (consuming dead wood), yet can be found growing on living trees as well. Many experts believe the mushroom has a mutualistic relationship with the tree for some time — helping it resist disease — before eventually consuming it after it dies. Hericium species have characteristic “tooth” structures on the fruiting body, giving it a hair-like appearance.

Pharmacology & Research

Lion’s mane has a large preclinical literature — well over a hundred in vitro and rodent studies — anchored by a small but genuine set of human trials, making it one of the better-evidenced medicinal mushrooms for cognition. The centre of gravity is neurological: the mushroom’s signature ability to stimulate nerve growth factor (NGF) via its hericenones and erinacines underpins most of its investigated uses ^{7,9Reference 7Spangenberg et al. · 2025Systematic reviewUnveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus — systematic reviewView study →Reference 9Friedman · 2015ReviewChemistry, nutrition, and health-promoting properties of Hericium erinaceus mushroom — reviewView study →}. Human evidence is real but thin and mixed — at least five randomised controlled trials exist, the strongest in older adults with mild cognitive impairment, while trials in healthy young adults are largely null or task-specific ^{1,2,3,4Reference 1Mori et al. · 2009RCTImproving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment — randomised, double-blind, placebo-controlled trialView study →Reference 2Saitsu et al. · 2019RCTImprovement of cognitive functions by oral intake of Hericium erinaceus — randomised, double-blind, placebo-controlled trialView study →Reference 3Docherty et al. · 2023RCTThe acute and chronic effects of lion’s mane mushroom supplementation on cognitive function, stress and mood in young adults — randomised, double-blind, placebo-controlled pilot trialView study →Reference 4Surendran et al. · 2025RCTAcute effects of a standardised extract of Hericium erinaceus on cognition and mood — randomised, placebo-controlled crossover trialView study →}. A critical caveat runs through the whole field: the two flagship compound families live in different tissues — hericenones in the fruiting body, erinacines in the submerged-culture mycelium — so results from a standardised erinacine-A mycelial extract do not transfer to a fruiting-body powder or a culinary preparation ^{5,7Reference 5Li et al. · 2020RCTPrevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia — randomised, double-blind, placebo-controlled pilot trialView study →Reference 7Spangenberg et al. · 2025Systematic reviewUnveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus — systematic reviewView study →}.

0. Evidence by indication

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric, and I’ll keep honing the formula over time. Each indication name links down to its write-up.

Indication	Support	Rests on
Cognitive function & MCI	███████░░░ 72%	Several small human RCTs positive in impaired older adults; null/task-specific in healthy young; fruiting-body powder & extracts
Neuroprotective (NGF-stimulating)	███████░░░ 68%	Strong molecule-to-animal NGF/neurotrophic mechanism + one mild-AD pilot RCT (mycelial erinacine A)
Depression & anxiety	██████░░░░ 58%	Two small human trials (menopausal, overweight cohorts) + mouse neurogenesis; specific populations
Peripheral nerve regeneration	█████░░░░░ 54%	Rodent crush-injury recovery + systematic review; no human data
Anti-inflammatory	█████░░░░░ 52%	In vitro human monocytes (ergosterol) + rodent NF-κB/TLR4 signalling
Immunomodulatory	█████░░░░░ 50%	Polysaccharide fractions activate dendritic/immune cells in vitro & in mice
Gastroprotective & GI mucosa	█████░░░░░ 48%	Rodent gastric-ulcer & colitis models, polysaccharide-driven; no human trials
Antioxidant	█████░░░░░ 46%	In vitro radical scavenging + rodent oxidative-stress markers; constituent-level
Anticancer	████░░░░░░ 42%	Cell-line apoptosis (prostate, gastric) + erinacine-A review; no in vivo human signal
Hepatoprotective	████░░░░░░ 42%	Rodent liver-injury & NAFLD models with polysaccharide fractions
Antidiabetic & hypolipidemic	████░░░░░░ 38%	Single streptozotocin diabetic-rat study; animal only
Anti-fatigue	███░░░░░░░ 33%	One mouse forced-swim study with polysaccharides; traditional tonic use

1. Cognitive function & MCI

The most-cited human evidence is a 2009 randomised, double-blind, placebo-controlled trial in 30 Japanese adults (aged 50-80) with mild cognitive impairment: 1 g of dried fruiting-body powder (as 250 mg tablets, 96% powder) three times daily for 16 weeks significantly raised cognitive-scale scores versus placebo, with improvement appearing by week 8 — but scores fell back within 4 weeks of stopping, so the effect requires continued intake and is not disease-modifying ^{1Reference 1Mori et al. · 2009RCTImproving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment — randomised, double-blind, placebo-controlled trialView study →}. A 2019 randomised, double-blind, placebo-controlled trial (12 weeks, fruiting-body supplement) found improvement on the MMSE but not on two other cognitive tests ^{2Reference 2Saitsu et al. · 2019RCTImprovement of cognitive functions by oral intake of Hericium erinaceus — randomised, double-blind, placebo-controlled trialView study →}. In healthy young adults the picture is weaker: a 2023 randomised, placebo-controlled trial (1.8 g, 41 adults) found faster Stroop performance 60 minutes after a single dose and only a non-significant trend toward reduced stress after 28 days ^{3Reference 3Docherty et al. · 2023RCTThe acute and chronic effects of lion’s mane mushroom supplementation on cognitive function, stress and mood in young adults — randomised, double-blind, placebo-controlled pilot trialView study →}, while a 2025 randomised, placebo-controlled crossover trial (3 g of a 10:1 fruiting-body extract, 18 adults) found no overall cognitive or mood effect, with benefit limited to a single pegboard task ^{4Reference 4Surendran et al. · 2025RCTAcute effects of a standardised extract of Hericium erinaceus on cognition and mood — randomised, placebo-controlled crossover trialView study →}. A 2025 systematic review pooling MMSE data from one RCT and one pilot trial reported a modest combined mean increase of ~1.2 points ^{28Reference 28Menon et al. · 2025Systematic reviewBenefits, side effects, and uses of Hericium erinaceus as a supplement — systematic reviewView study →}.

Gap: All positive trials are small (n≤30 per arm), mostly in impaired or older cohorts, and use different preparations and dose forms; the healthy-adult data are largely null. No large, long-duration confirmatory RCT exists.

2. Neuroprotective (NGF-stimulating)

Lion’s mane’s neurological reputation rests on a genuinely well-mapped mechanism: its low-molecular-weight aromatic compounds stimulate synthesis of nerve growth factor (NGF), the dominant trophic factor for cholinergic neurons, which itself barely crosses the blood-brain barrier — so compounds that raise it within the CNS are of real interest ^{7,9Reference 7Spangenberg et al. · 2025Systematic reviewUnveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus — systematic reviewView study →Reference 9Friedman · 2015ReviewChemistry, nutrition, and health-promoting properties of Hericium erinaceus mushroom — reviewView study →}. The fruiting-body hericenones and mycelial erinacines both drive NGF; a 2023 study isolated hericerin-derived compounds including hericene A that activated a pan-neurotrophic (TrkB/ERK) pathway and enhanced spatial memory in mice ^{6Reference 6Martínez-Mármol et al. · 2023In vitroHericerin derivatives activate a pan-neurotrophic pathway in central hippocampal neurons — in vitro and mouse studyView study →}. Downstream neuroprotective effects shown in cell and rodent models include reduced endoplasmic-reticulum-stress cell death, attenuation of beta-amyloid toxicity, and enhanced oligodendrocyte maturation and myelination ^{8Reference 8Huang et al. · 2021In vitroHericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation — in vitro studyView study →}. The one clinical anchor is a 2020 randomised, double-blind, placebo-controlled pilot trial in mild Alzheimer’s disease: three erinacine-A-enriched mycelial capsules daily for 49 weeks improved MMSE and daily-living scores and contrast sensitivity versus placebo, and was well tolerated (registered as NCT04065061) ^{5Reference 5Li et al. · 2020RCTPrevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia — randomised, double-blind, placebo-controlled pilot trialView study →}. A 2025 systematic review of erinacines confirmed consistent neurotrophic and neuroprotective activity across cellular and rodent models but flagged the near-total reliance on preclinical work ^{7Reference 7Spangenberg et al. · 2025Systematic reviewUnveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus — systematic reviewView study →}.

Gap: The neuroprotection evidence is overwhelmingly preclinical; the single mild-AD RCT is small and used a specific mycelial erinacine A extract that does not correspond to fruiting-body products.

3. Depression & anxiety

Two small human trials support a mood effect. A 2010 randomised, placebo-controlled trial gave 30 menopausal women fruiting-body cookies for 4 weeks and found significantly lower depression (CES-D) and several “indefinite complaint” scores versus placebo — the authors noted the effect appeared distinct from NGF-enhancement ^{10Reference 10Nagano et al. · 2010RCTReduction of depression and anxiety by 4 weeks Hericium erinaceus intake — randomised, placebo-controlled trialView study →}. A 2019 controlled trial in 77 overweight/obese volunteers reported reduced depression, anxiety and sleep disturbance after 8 weeks, alongside raised circulating pro-BDNF (but not mature BDNF) ^{11Reference 11Vigna et al. · 2019Clinical trialHericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity — controlled trialView study →}. Mechanistically, a 2018 mouse study showed a fruiting-body extract reduced anxiety- and depression-like behaviour while promoting hippocampal neurogenesis ^{12Reference 12Ryu et al. · 2018AnimalHericium erinaceus extract reduces anxiety and depressive behaviors by promoting hippocampal neurogenesis in the adult mouse brain — animal modelView study →}.

Gap: Both human trials are small, unblinded or single-population (menopausal, obese), and short; there is no trial in diagnosed major depression, and the biomarker findings (pro-BDNF up, BDNF unchanged) are hard to interpret.

4. Peripheral nerve regeneration

In rodent nerve-crush models, aqueous fruiting-body extract accelerated functional recovery: a study in rats with peroneal-nerve crush injury showed faster axonal regeneration and reinnervation, mediated through Akt/MAPK signalling and c-Jun/c-Fos in the dorsal root ganglia ^{13Reference 13Wong et al. · 2016AnimalHericium erinaceus activates peripheral nerve regeneration after peroneal-nerve crush — rat in vivo studyView study →}. A 2026 systematic review of medicinal mushrooms for peripheral nerve injury identified lion’s mane as one of the better-characterised candidates while concluding the mechanisms and clinical relevance remain incompletely defined ^{14Reference 14Taib et al. · 2026Systematic reviewApplication of medicinal mushrooms for the treatment of peripheral nerve injury — systematic reviewView study →}.

Gap: Entirely preclinical — no human trial has tested lion’s mane for nerve injury or neuropathy, and effective rodent doses/extracts are not established for people.

5. Anti-inflammatory

Lion’s mane modulates several inflammatory pathways. A 2022 study found that an ethanol extract and its constituent ergosterol neutralised LPS-induced production of IL-1β, IL-6 and IL-8 in human monocytes in vitro ^{15Reference 15Tada et al. · 2022In vitroHericium erinaceus ethanol extract and ergosterol exert anti-inflammatory activities in human monocytes — in vitro studyView study →}. In rodent models the mushroom lowers pro-inflammatory mediators via NF-κB and TLR4/JNK signalling, an effect that overlaps with its gut and neuroprotective actions ^{20Reference 20Diling et al. · 2017AnimalExtracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and microbiota — rat modelView study →}.

Gap: The human-cell data are in vitro only; no clinical trial has measured inflammatory endpoints, and effects are reported for varied extracts and isolated constituents rather than a defined whole-mushroom dose.

6. Immunomodulatory

Like most medicinal mushrooms, lion’s mane is rich in beta-glucans and other polysaccharides with immune-activating properties. Isolated and chemically modified polysaccharide fractions promote maturation and activation of dendritic cells through MAPK and NF-κB signalling in vitro ^{16Reference 16Qin et al. · 2017In vitroSelenizing Hericium erinaceus polysaccharides induce dendritic-cell maturation through MAPK and NF-κB signaling — in vitro studyView study →}, and structurally characterised fractions show immunomodulatory activity in cell assays ^{17Reference 17Yang et al. · 2022In vitroPolysaccharides from Hericium erinaceus fruiting bodies: structural characterization and immunomodulatory activity — in vitro studyView study →}. In a 2012 mouse study, fruiting-body extracts protected against Salmonella Typhimurium liver damage and mortality by stimulating innate immune (macrophage) uptake rather than by direct antibacterial action ^{18Reference 18Kim et al. · 2012AnimalHericium erinaceus mushroom extracts protect infected mice against Salmonella Typhimurium-induced liver damage — animal modelView study →}.

Gap: Effects are driven by isolated polysaccharide fractions in animal and cell models; there is no human immune-outcome trial, and the fractions used are not the form consumers ingest.

7. Gastroprotective & GI mucosa

Polysaccharide fractions protect the gut lining in rodent models. In a 2022 study, fruiting-body polysaccharide reduced acetic-acid-induced gastric ulceration in rats, lowering IL-6, TNF-α and oxidative markers ^{19Reference 19Wang et al. · 2022AnimalGastroprotective activity of polysaccharide from Hericium erinaceus against acetic-acid-induced gastric ulcer — rat in vivo studyView study →}; extracts also relieved TNBS-induced colitis in rats by modulating immunity and the microbiota ^{20Reference 20Diling et al. · 2017AnimalExtracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and microbiota — rat modelView study →}. A 2023 review catalogued consistent preclinical activity across gastritis, ulcer and inflammatory-bowel-disease models and highlighted lion’s mane’s traditional East-Asian use for gastrointestinal complaints ^{21Reference 21Gravina et al. · 2023ReviewHericium erinaceus, a medicinal fungus: evidence in gastrointestinal diseases — reviewView study →}.

Gap: All efficacy data are rodent or in vitro; despite strong traditional GI use and registered trials, no completed human trial confirms a gastroprotective effect.

8. Antioxidant

Lion’s mane extracts and polysaccharides show free-radical scavenging in vitro and reduce oxidative-stress markers in animals. A 2012 study of mycelial endo-polysaccharide fractions found strong in vitro antioxidant activity and a hepatoprotective effect in mice, with the most active fraction linked to its antioxidant capacity ^{22Reference 22Zhang et al. · 2012In vitroAntioxidant and hepatoprotective potential of endo-polysaccharides from Hericium erinaceus — in vitro and mouse studyView study →}. Antioxidant activity is a recurring mechanistic thread underlying the neuroprotective, hepatoprotective and anti-inflammatory findings rather than a stand-alone clinical use ^{9Reference 9Friedman · 2015ReviewChemistry, nutrition, and health-promoting properties of Hericium erinaceus mushroom — reviewView study →}.

Gap: Antioxidant activity is measured chiefly in chemical assays and animal tissue; it has not been shown to translate into a clinical antioxidant benefit, and results vary widely with extract and fraction.

9. Anticancer

Anticancer evidence is preclinical and constituent-focused. A 2024 study reported that an ethanol fruiting-body extract induced apoptosis in prostate cancer cells via PI3K/AKT and RAS/MAPK signalling in vitro ^{23Reference 23Atmaca et al. · 2024In vitroHericium erinaceus extract induces apoptosis via PI3K/AKT and RAS/MAPK signaling in prostate cancer cells — in vitro studyView study →}. A 2020 review of erinacine A and related cyathane diterpenoids summarised in vitro and animal antitumour activity — including inhibition of gastric-cancer-cell invasiveness and caspase activation — alongside their neuroprotective effects ^{24Reference 24Bailly · 2020ReviewErinacine A and related cyathane diterpenoids: mechanisms underlying their neuroprotection and anticancer activities — reviewView study →}.

Gap: No in vivo human evidence; findings are cell-line apoptosis assays and isolated-compound reviews, and the doses have no established relationship to oral supplementation.

10. Hepatoprotective

In rodent and cell models, lion’s mane polysaccharides protect the liver. Mycelial endo-polysaccharide fractions showed a potent hepatoprotective effect in vivo in mice, apparently linked to their antioxidant capacity ^{22Reference 22Zhang et al. · 2012In vitroAntioxidant and hepatoprotective potential of endo-polysaccharides from Hericium erinaceus — in vitro and mouse studyView study →}. Related work reports protection against high-fat-diet-induced fatty liver and hepatotoxicity, again driven by polysaccharide fractions.

Gap: Animal-only; no human liver-outcome data, and the active material is isolated polysaccharide rather than a standard whole-mushroom product.

11. Antidiabetic & hypolipidemic

A 2013 study in streptozotocin-induced diabetic rats found that aqueous fruiting-body extract (100 and 200 mg/kg for 28 days) lowered blood glucose, improved insulin and lipid profiles, and reduced hepatic oxidative-stress markers ^{25Reference 25Liang et al. · 2013AnimalAntihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericium erinaceus in experimental diabetic rats — animal modelView study →}.

Gap: A single rodent model with no human confirmation; effects on glucose or lipids in people are untested.

12. Anti-fatigue

A 2015 mouse study reported that lion’s mane polysaccharides (50-200 mg/kg for 28 days) extended forced-swim endurance and shifted biochemical fatigue markers, consistent with the mushroom’s traditional use as a general tonic ^{26Reference 26Liu et al. · 2015AnimalAnti-fatigue activities of polysaccharides extracted from Hericium erinaceus — mouse in vivo studyView study →}.

Gap: One animal study only; there is no human trial of exercise capacity or fatigue, and the effect is attributed to polysaccharide fractions.

Mechanisms

Mechanism	Drives	Key compounds
NGF synthesis ↑ (TrkA/TrkB, ERK1/2)	neuroprotective, cognitive, nerve regeneration	hericene A, erinacine A, hericenones, erinacines
NF-κB ↓, TLR4/JNK ↓, cytokine ↓	anti-inflammatory, gastroprotective	ergosterol, polysaccharides
Dendritic-cell & macrophage activation	immunomodulatory	beta-glucans, polysaccharides
Free-radical scavenging, oxidative-stress ↓	antioxidant, hepatoprotective, neuroprotective	polysaccharides, phenolics
Pro-apoptotic (PI3K/AKT, caspase, RAS/MAPK)	anticancer	erinacine A, cyathane diterpenoids
Hippocampal neurogenesis ↑, pro-BDNF ↑	mood (depression/anxiety)	fruiting-body extract

Clinical trials

Twelve trials are registered on ClinicalTrials.gov — five completed (mostly cognition), two recruiting (cancer-related fatigue, cognitive decline), and five with unknown/stalled status (tinnitus, depression, Parkinson’s, colorectal-surgery recovery, PMS); none has been terminated, but the completed set is small and dominated by cognitive endpoints.

Completed	Planned	Terminated	Preclinical
5	2	0	~100+

Plus 5 registered trials with unknown/stalled status (tinnitus, major depression, Parkinson’s, colorectal-surgery recovery, PMS), not shown in the table above — 12 registered in total.

Last checked: July 2026.

Phytochemistry

The fruiting body and mycelia contain a diverse range of bioactive substances — polysaccharides, meroterpenoids, cyathane diterpenoids, steroids, alkaloids, and lactones. The most significant medicinally are the aromatic hericenones, found only in the fruiting body, and the erinacines, cyathane diterpenoids concentrated in the submerged-culture mycelium — both shown to stimulate nerve growth factor in the central nervous system. The bulk of the dried mushroom is carbohydrate, dominated by immunomodulatory beta-glucans and related polysaccharides.

Constituent Summary

Figures are percent of the dried fruiting body (beta-glucan/polysaccharide) or the localising tissue; hericenones and erinacines are reported qualitatively as fruiting-body- vs mycelium-specific markers rather than as fixed percentages, so are listed as No Data for amount. Values vary widely with strain, substrate and extraction.

Clinical Applications

Lion’s mane is best known as a neuroprotective and nootropic agent. The human evidence is strongest for cognition (mild cognitive impairment and early Alzheimer’s) and mood (depression and anxiety in small trials); its use for multiple sclerosis and Parkinson’s rests on preclinical oligodendrocyte/neuroprotection work rather than human trials, and the cancer, diabetes and gastrointestinal uses remain cell-line and animal findings. It is best taken consistently over the long term rather than in short bursts.

Dosage

Almost all of lion’s mane’s clinical evidence uses dried fruiting-body powder or extract at 1–3 g/day, or an erinacine-A-enriched mycelial capsule — not the tincture the sidebar quotes. Because hericenones (fruiting body) and erinacines (mycelium) come from different tissues, these preparations are not interchangeable.

Indication	Preparation	Dose	Est. dried-herb equivalent	Source
Mild cognitive impairment	Dried fruiting-body powder (96% powder tablets)	3 g/day (1 g × 3), 16 wk	~3 g dried fruiting body	1Reference 1Mori et al. · 2009RCTImproving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment — randomised, double-blind, placebo-controlled trialView study →
Cognitive function (older adults)	Fruiting-body supplement	daily, 12 wk	— (proprietary; per-g dose not stated)	2Reference 2Saitsu et al. · 2019RCTImprovement of cognitive functions by oral intake of Hericium erinaceus — randomised, double-blind, placebo-controlled trialView study →
Cognition/mood (healthy young)	Fruiting-body supplement	1.8 g/day, 28 days	~1.8 g dried fruiting body	3Reference 3Docherty et al. · 2023RCTThe acute and chronic effects of lion’s mane mushroom supplementation on cognitive function, stress and mood in young adults — randomised, double-blind, placebo-controlled pilot trialView study →
Cognition/mood (acute, healthy)	10:1 fruiting-body extract	3 g single dose	~30 g dried-herb-equivalent (nominal 10:1)	4Reference 4Surendran et al. · 2025RCTAcute effects of a standardised extract of Hericium erinaceus on cognition and mood — randomised, placebo-controlled crossover trialView study →
Mild Alzheimer’s disease	Erinacine-A-enriched mycelium capsules (350 mg, 5 mg/g erinacine A)	1050 mg/day (3 caps), 49 wk	— (mycelial extract; not fruiting-body-equivalent)	5Reference 5Li et al. · 2020RCTPrevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia — randomised, double-blind, placebo-controlled pilot trialView study →
Depression/anxiety (menopausal)	Fruiting-body powder in cookies	daily, 4 wk	— (per-serving amount not standardised)	10Reference 10Nagano et al. · 2010RCTReduction of depression and anxiety by 4 weeks Hericium erinaceus intake — randomised, placebo-controlled trialView study →
Mood/sleep (overweight)	Fruiting-body supplement	daily, 8 wk	— (proprietary)	11Reference 11Vigna et al. · 2019Clinical trialHericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity — controlled trialView study →

Estimates only, not conversion factors or recommendations: whole-powder trials are taken at face value (the dose is dried fruiting body); the 10:1 extract’s ~30 g equivalent is an order-of-magnitude figure; mycelial erinacine-A extracts cannot be back-converted to fruiting-body weight (different tissue and chemistry), so are left ”—”.

Traditional Dosage

System	Preparation	Dose
Western herbal	Liquid extract (1:2)	20–60 mL / week
Western herbal	Dried fruiting body (decoction / powder)	3–5 g / day
TCM (Houtou / Yamabushitake)	Decoction of dried fruiting body	traditionally for gastric complaints and general debility

Safety

Lion’s mane is an edible culinary mushroom with a strong safety record: no serious adverse events have been reported in the clinical trials to date, and both a GLP subchronic-toxicity/genotoxicity study (NOAEL 2000 mg/kg/day, the highest dose tested) and an acute/developmental-toxicity study in rats found no toxic or genotoxic effects ^{27,29Reference 27Chen et al. · 2022AnimalSubchronic toxicity and genotoxicity studies of Hericium erinaceus β-glucan extract preparation — GLP rat studyView study →Reference 29Li et al. · 2018AnimalAcute and developmental toxicity assessment of erinacine-A-enriched Hericium erinaceus mycelia in Sprague-Dawley rats — animal studyView study →}. The most commonly reported side effects in human use are mild — stomach or abdominal discomfort, nausea, headache, and occasional allergic skin reactions ^{28Reference 28Menon et al. · 2025Systematic reviewBenefits, side effects, and uses of Hericium erinaceus as a supplement — systematic reviewView study →}. Because it is a fungus, people with mushroom or mould allergies should exercise caution, and there is a theoretical concern about additive effects with anticoagulant or antiplatelet medication, though no interaction has been formally documented in humans ^{28Reference 28Menon et al. · 2025Systematic reviewBenefits, side effects, and uses of Hericium erinaceus as a supplement — systematic reviewView study →}. As with most medicinal mushrooms, the strongest, most consistent benefits come from regular long-term use.

Scope of this assessment: no human drug-interaction study exists — the anticoagulant/antiplatelet caution is precautionary, based on the herb’s general profile, not a documented case. Pregnancy and lactation safety is unstudied in humans (only a single rat developmental-toxicity study exists).

Pregnancy & lactation

Not established. Lion’s mane has not been tested for safety in human pregnancy or lactation; a rat developmental-toxicity study of an erinacine-A-enriched mycelial extract found no fetal harm at doses up to 2625 mg/kg ^{29Reference 29Li et al. · 2018AnimalAcute and developmental toxicity assessment of erinacine-A-enriched Hericium erinaceus mycelia in Sprague-Dawley rats — animal studyView study →}, but animal data do not establish human safety. Given the absence of human data, the precautionary approach is to avoid concentrated supplemental doses during pregnancy and breastfeeding, while culinary amounts of the cooked mushroom are generally regarded as food.

---

Author: Justin Cooke, BHSc — The Sunlight Experiment (updated April 2020)

References

1. Mori, K., et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment — randomised, double-blind, placebo-controlled trial. Phytother Res. https://pubmed.ncbi.nlm.nih.gov/18844328/
2. Saitsu, Y., et al. (2019). Improvement of cognitive functions by oral intake of Hericium erinaceus — randomised, double-blind, placebo-controlled trial. Biomed Res. https://pubmed.ncbi.nlm.nih.gov/31413233/
3. Docherty, S., et al. (2023). The acute and chronic effects of lion’s mane mushroom supplementation on cognitive function, stress and mood in young adults — randomised, double-blind, placebo-controlled pilot trial. Nutrients. https://pubmed.ncbi.nlm.nih.gov/38004235/
4. Surendran, G., et al. (2025). Acute effects of a standardised extract of Hericium erinaceus on cognition and mood — randomised, placebo-controlled crossover trial. Front Nutr. https://pubmed.ncbi.nlm.nih.gov/40276537/
5. Li, I. C., et al. (2020). Prevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia — randomised, double-blind, placebo-controlled pilot trial. Front Aging Neurosci. https://pubmed.ncbi.nlm.nih.gov/32581767/
6. Martínez-Mármol, R., et al. (2023). Hericerin derivatives activate a pan-neurotrophic pathway in central hippocampal neurons — in vitro and mouse study. J Neurochem. https://pubmed.ncbi.nlm.nih.gov/36660878/
7. Spangenberg, E. T., et al. (2025). Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus — systematic review. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/40626304/
8. Huang, H. T., et al. (2021). Hericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation — in vitro study. Sci Rep. https://pubmed.ncbi.nlm.nih.gov/33753806/
9. Friedman, M. (2015). Chemistry, nutrition, and health-promoting properties of Hericium erinaceus mushroom — review. J Agric Food Chem. https://pubmed.ncbi.nlm.nih.gov/26244378/
10. Nagano, M., et al. (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake — randomised, placebo-controlled trial. Biomed Res. https://pubmed.ncbi.nlm.nih.gov/20834180/
11. Vigna, L., et al. (2019). Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity — controlled trial. Evid Based Complement Alternat Med. https://pubmed.ncbi.nlm.nih.gov/31118969/
12. Ryu, S., et al. (2018). Hericium erinaceus extract reduces anxiety and depressive behaviors by promoting hippocampal neurogenesis in the adult mouse brain — animal model. J Med Food. https://pubmed.ncbi.nlm.nih.gov/29091526/
13. Wong, K. H., et al. (2016). Hericium erinaceus activates peripheral nerve regeneration after peroneal-nerve crush — rat in vivo study. Chin J Integr Med. https://pubmed.ncbi.nlm.nih.gov/25159861/
14. Taib, N. A. B., et al. (2026). Application of medicinal mushrooms for the treatment of peripheral nerve injury — systematic review. Med Sci (Basel). https://pubmed.ncbi.nlm.nih.gov/41562932/
15. Tada, H., et al. (2022). Hericium erinaceus ethanol extract and ergosterol exert anti-inflammatory activities in human monocytes — in vitro study. Biochem Biophys Res Commun. https://pubmed.ncbi.nlm.nih.gov/36335857/
16. Qin, T., et al. (2017). Selenizing Hericium erinaceus polysaccharides induce dendritic-cell maturation through MAPK and NF-κB signaling — in vitro study. Int J Biol Macromol. https://pubmed.ncbi.nlm.nih.gov/28089932/
17. Yang, Y., et al. (2022). Polysaccharides from Hericium erinaceus fruiting bodies: structural characterization and immunomodulatory activity — in vitro study. Nutrients. https://pubmed.ncbi.nlm.nih.gov/36145096/
18. Kim, S. P., et al. (2012). Hericium erinaceus mushroom extracts protect infected mice against Salmonella Typhimurium-induced liver damage — animal model. J Agric Food Chem. https://pubmed.ncbi.nlm.nih.gov/22624604/
19. Wang, X. Y., et al. (2022). Gastroprotective activity of polysaccharide from Hericium erinaceus against acetic-acid-induced gastric ulcer — rat in vivo study. Int J Biol Macromol. https://pubmed.ncbi.nlm.nih.gov/35483513/
20. Diling, C., et al. (2017). Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and microbiota — rat model. Oncotarget. https://pubmed.ncbi.nlm.nih.gov/29156761/
21. Gravina, A. G., et al. (2023). Hericium erinaceus, a medicinal fungus: evidence in gastrointestinal diseases — review. World J Gastroenterol. https://pubmed.ncbi.nlm.nih.gov/37346156/
22. Zhang, Z., et al. (2012). Antioxidant and hepatoprotective potential of endo-polysaccharides from Hericium erinaceus — in vitro and mouse study. Int J Biol Macromol. https://pubmed.ncbi.nlm.nih.gov/22982810/
23. Atmaca, H., et al. (2024). Hericium erinaceus extract induces apoptosis via PI3K/AKT and RAS/MAPK signaling in prostate cancer cells — in vitro study. Chem Biodivers. https://pubmed.ncbi.nlm.nih.gov/39183463/
24. Bailly, C. (2020). Erinacine A and related cyathane diterpenoids: mechanisms underlying their neuroprotection and anticancer activities — review. Pharmacol Res. https://pubmed.ncbi.nlm.nih.gov/32485283/
25. Liang, B., et al. (2013). Antihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericium erinaceus in experimental diabetic rats — animal model. BMC Complement Altern Med. https://pubmed.ncbi.nlm.nih.gov/24090482/
26. Liu, J., et al. (2015). Anti-fatigue activities of polysaccharides extracted from Hericium erinaceus — mouse in vivo study. Exp Ther Med. https://pubmed.ncbi.nlm.nih.gov/25574220/
27. Chen, S. N., et al. (2022). Subchronic toxicity and genotoxicity studies of Hericium erinaceus β-glucan extract preparation — GLP rat study. Curr Res Toxicol. https://pubmed.ncbi.nlm.nih.gov/35341120/
28. Menon, A., et al. (2025). Benefits, side effects, and uses of Hericium erinaceus as a supplement — systematic review. Front Nutr. https://pubmed.ncbi.nlm.nih.gov/40959699/
29. Li, I. C., et al. (2018). Acute and developmental toxicity assessment of erinacine-A-enriched Hericium erinaceus mycelia in Sprague-Dawley rats — animal study. Drug Chem Toxicol. https://pubmed.ncbi.nlm.nih.gov/29359595/
30. Muhanna, M., et al. (2024). ALSUntangled #73: Lion’s Mane — review. Amyotroph Lateral Scler Frontotemporal Degener. https://pubmed.ncbi.nlm.nih.gov/38141002/